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 Abstract 
 Anti-angiogenic therapies have shown limited efficacy in the clinical management of 
metastatic disease, including lung metastases. Moreover, the mechanisms via which 
tumours resist anti-angiogenic therapies are poorly understood. Importantly, rather than 
utilising angiogenesis, some metastases may instead incorporate pre-existing vessels from 
surrounding tissue (vessel co-option). Since anti-angiogenic therapies were designed to 
target only new blood vessel growth, vessel co-option has been proposed as a mechanism 
that could drive resistance to anti-angiogenic therapy. However, vessel co-option has not 
been extensively studied in lung metastases, and its potential to mediate resistance to anti-
angiogenic therapy in lung metastases is not established. Here we examine the mechanism 
of tumour vascularisation in 164 human lung metastasis specimens (composed of breast, 
colorectal and renal cancer lung metastasis cases). We identify four distinct histopathological 
growth patterns (HGPs) of lung metastasis (alveolar, interstitial, perivascular cuffing and 
pushing) that each vascularise via a different mechanism. In the alveolar HGP, cancer cells 
invade the alveolar air spaces, which facilitates the co-option of alveolar capillaries. In the 
interstitial HGP, cancer cells invade into the alveolar walls to co-opt alveolar capillaries. In 
the perivascular cuffing HGP, cancer cells grow by co-opting larger vessels of the lung. Only 
in the pushing HGP did the tumours vascularise by angiogenesis. Importantly, vessel co-
option occurred with high frequency, being present in over 80% of the cases examined. 
Moreover, we provide evidence that vessel co-option mediates resistance to the anti-
angiogenic drug sunitinib in preclinical lung metastasis models. Assuming that our 
interpretation of the data is correct, we conclude that vessel co-option in lung metastases 
occurs through at least three distinct mechanisms, that vessel co-option occurs frequently in 
lung metastases and that vessel co-option could mediate resistance to anti-angiogenic 
therapy in lung metastases.  Novel therapies designed to target both angiogenesis and 
vessel co-option are therefore warranted. 
Keywords: lung metastasis, angiogenesis, vessel co-option, anti-angiogenic therapy, 
sunitinib, drug resistance 
 Introduction 
 Although the progression of metastases is considered to require new blood vessel 
growth (angiogenesis), anti-angiogenic drugs have shown limited efficacy in patients with 
metastatic disease. Metastases can be either unresponsive to anti-angiogenic therapy from 
the outset (intrinsic resistance) or can develop resistance after an initial period of response 
(acquired resistance). The mechanisms that mediate this resistance are still poorly 
understood [1-5].  
 However, rather than inducing angiogenesis, it now emerges that some tumours can 
instead incorporate pre-existing blood vessels from the surrounding normal tissue, a process 
known as vessel co-option or vascular co-option [5-7]. For example, seminal studies on non-
small cell lung cancer (NSCLC) demonstrated that some NSCLCs utilise vessel co-option 
instead of angiogenesis [8-12]. In this ‘non-angiogenic’ subtype of NSCLC, the cancer cells 
grow only within the alveolar air spaces. This permits intact alveolar walls to be incorporated 
into the tumour, allowing the tumour to co-opt the alveolar capillaries that are contained 
within those alveolar walls [8-12]. A similar presentation has been reported in some cases of 
human lung metastasis [13-15]. In addition, we recently examined the mechanism of tumour 
vascularisation in several preclinical models of lung metastasis. In all models examined, the 
lung metastases co-opted alveolar capillaries by occupying the alveolar air spaces [16].  
 Given that conventional anti-angiogenic drugs were designed only to inhibit 
angiogenesis, the presence of vessel co-option in tumours may help to explain the limited 
efficacy of conventional anti-angiogenic therapies [7]. In support of this, vessel co-option has 
now been implicated as a mechanism of resistance to anti-angiogenic drugs in glioblastoma 
[17-19], hepatocellular carcinoma [20], lymph node metastases [21], liver metastases [22] 
and brain metastases [23,24]. However, a role for vessel co-option in driving therapy 
resistance in lung metastases has not been reported.  
 In the current study, we describe three distinct mechanisms of vessel co-option in 
human lung metastases. We also quantify the incidence of vessel co-option across a large 
 series of human lung metastasis cases. Finally, we utilise preclinical lung metastasis models 
to investigate whether vessel co-option can mediate resistance to anti-angiogenic therapy. 
 
 
  
 Materials and methods 
 
Human samples 
Formalin-fixed paraffin-embedded (FFPE) samples of human lung metastases were 
retrieved from archives at the St Augustinus Hospital (Antwerp, Belgium), the Medical 
University of Vienna (Vienna, Austria) and the National Koranyi Institute of Pulmonology 
(Budapest, Hungary). This initial series consisted of 193 lesions from 181 patients. 
Haematoxylin and eosin (H&E) stained sections were prepared from all cases for an initial 
histopathological assessment. 29 lesions were then excluded because they were unsuitable 
(see Supplementary Figures S1-S3). The final series analysed consisted of 164 lesions from 
158 patients (46 breast cancer metastases from 46 patients, 57 colorectal cancer 
metastases from 53 patients, and 61 renal cancer metastases from 59 patients). For patient 
details see Supplementary Tables S1-S3. Ethical approval was obtained from the Research 
Ethics Committee of the GZA Hospitals St. Augustinus, the Ethics Committee of the Medical 
University of Vienna and the National Scientific and Ethics Committee of Hungary. 
 
Staining of tissue sections, histopathological analysis and preclinical models 
 Details of the procedures that were used for: tissue staining, scoring of 
histopathological growth patterns, scoring of breast cancer subtypes (which were determined 
as per published guidelines [25-27]) and in vivo models can be found in Supplementary 
Methods. The Institute of Cancer Research Animal Ethics Committee granted approval for 
animal work and procedures were performed in accordance with the United Kingdom Home 
Office regulations. 
 
Statistical analysis 
 Statistical analysis was performed using two-tailed Fisher’s exact test or two-tailed 
Student’s t-test. P-values below 0.05 were considered significant. 
 Results 
 
Human lung metastases present with distinct growth patterns that are associated with 
different vascularisation mechanisms  
 To investigate the mechanisms of tumour vascularisation in human lung metastases, 
we performed a histopathological analysis on 164 human lung metastasis cases (46 breast 
cancer metastases, 57 colorectal cancer metastases and 61 renal cancer metastases). We 
identified four distinct histopathological growth patterns (HGPs): the alveolar HGP, interstitial 
HGP, perivascular cuffing HGP and the pushing HGP. We present evidence that although 
pushing HGP lung metastases utilise angiogenesis, tumour vascularisation occurs through 
vessel co-option in the alveolar, interstitial and perivascular cuffing HGPs. 
 
Co-option of alveolar capillaries in the alveolar growth pattern 
 In previous studies, incorporation of intact alveolar walls into lung metastases has 
been cited as evidence that these tumours co-opt pre-existing alveolar capillaries [13,14,16]. 
In order to robustly identify the presence of alveolar walls in human tissue specimens we 
performed staining for the established pneumocyte marker cytokeratin-7 (CK7) [28]. In 
normal human lung, CK7 staining demonstrated a network of CK7-positive alveolar walls 
separated by intervening alveolar air spaces (Figure 1A). This ‘honeycomb’ morphology is 
characteristic of normal human lung parenchyma. Staining for a second established 
pneumocyte marker, thyroid transcription factor (TTF1) [29], gave similar results. 
 We then performed staining for pneumocytes in samples of human breast cancer 
lung metastases. This approach clearly demonstrated two of the growth patterns of human 
lung metastases: the alveolar HGP and the pushing HGP. In the alveolar HGP, the cancer 
cells at the periphery of the metastasis entered the alveolar air spaces of the lung, which led 
to the incorporation of intact alveolar walls into the tumour (Figure 1C). In contrast, in the 
pushing HGP, the cancer cells did not enter the alveolar air spaces.  Instead, the alveolar 
walls at the periphery of the metastases were pushed away by the tumour (Figure 1E).  
  Additionally, we examined blood vessels by staining for the vascular endothelial 
marker CD31. In normal human lung, a honeycomb network of CD31-positive alveolar walls, 
separated by intervening alveolar air spaces, was observed (Figure 1B). Importantly, in 
metastases with an alveolar HGP, the tumour vessel architecture closely resembled the 
vascular architecture of the normal lung (Figure 1D), suggesting that these tumours do co-
opt pre-existing alveolar capillaries by growing within the alveolar air spaces [8-10,13]. 
However, in sharp contrast, pushing HGP metastases contained abnormal and chaotically 
organised vessels (Figure 1F), which is typical of vessels generated by tumour angiogenesis 
[8-10,13]. Equivalent growth patterns were observed in both colorectal cancer and renal 
cancer lung metastases (Supplementary Figures S4 and S5). Our interpretation of these data 
is that whilst alveolar HGP lung metastases utilise vessel co-option to obtain a vascular 
supply, the pushing HGP lung metastases utilise angiogenesis.  
 To further characterise the mechanism of vessel co-option, lung metastases were co-
stained for CK7 and CD31. In normal lung, this staining demonstrated the architecture of the 
normal alveolar walls, which are lined by CK7-positive pneumocytes and contain CD31-
positive alveolar capillaries (Figure 2A). At the tumour-lung interface of alveolar HGP 
metastases, cancer cells invaded into the air spaces facilitating the co-option of CD31/CK7-
positive alveolar walls into the metastases (Figure 2B).  Just behind the tumour-lung 
interface, the alveolar air spaces were fully occupied with cancer cells, but the co-opted 
CD31/CK7-positive alveolar walls remained intact (Figure 2C and Supplementary Figure 
S6A-C). Co-opted alveolar capillaries often contained erythrocytes, confirming that the co-
opted blood vessels were perfused (Supplementary Figure S6D,E). 
 Moving towards the centre of the metastases, CD31-positive alveolar capillaries could 
be found that were now only partially associated with CK7-positive pneumocytes, suggesting 
that alveolar epithelium is gradually lost from co-opted alveolar capillaries (Figure 2D). To 
further corroborate this, alveolar HGP lung metastases stained for CK7 were viewed at low 
power. Whilst pneumocyte-rich alveolar walls were incorporated at the periphery of the 
metastases, a gradual loss of pneumocytes towards the centre of the metastases was 
 evident (Supplementary Figure S7). Our interpretation of these data is that cancer cells first 
co-opt alveolar walls by invading into the alveolar air spaces and that, subsequently, 
pneumocytes are gradually lost from these co-opted alveolar walls. However, after loss of 
these pneumocytes, the co-opted alveolar capillaries are retained by the tumour. By contrast, 
in pushing HGP lung metastases we found no incorporation of alveolar walls into the tumour, 
suggesting that pushing HGP lung metastases do not co-opt alveolar capillaries (Figure 
2E,F). 
  
Co-option of alveolar capillaries in the interstitial growth pattern  
 In this study we also observed a second growth pattern via which human lung 
metastases may co-opt alveolar capillaries. In the interstitial HGP, cancer cells were seen to 
co-opt alveolar capillaries by growing within the alveolar walls of the lung. The interstitial 
HGP is illustrated here using a case of renal cancer lung metastasis (Figure 3). Co-staining 
for carbonic anhydrase 9 (CAIX), to detect renal cancer cells, and CK7, to detect 
pneumocytes, demonstrates the infiltration of cancer cells into the normal alveolar walls at 
the tumour-lung interface (Figure 3A). To corroborate that this mode of infiltrative growth 
permits co-option of alveolar capillaries, co-staining for CAIX and CD31 was utilised. Close 
inspection of the alveolar walls at the tumour-lung interface demonstrated thin columns of 
cancer cells invading through the alveolar interstitium between the pre-existing alveolar 
capillaries (Figure 3B). Our interpretation of these data is that cancer cells can also invade 
through the alveolar walls to facilitate the co-option of alveolar capillaries. 
 Just behind the tumour-lung interface, CAIX-positive cancer cells completely filled the 
alveolar walls, but the intervening alveolar air spaces were preserved (Figure 3C). 
Importantly, these cancer-filled alveolar walls contained an abundance of co-opted alveolar 
capillaries (Figure 3D). Deeper into the metastasis, expansion of the cancer cell population 
resulted in significant broadening of the alveolar walls, but the intervening alveolar air spaces 
were mostly still preserved (Figure 3E). Some invasion of cancer cells into the alveolar air 
spaces was, however, also detected in the centre of the metastasis (Figure 3E). Within the 
 metastasis, we often observed blood vessels that were closely associated with the abluminal 
side of the air spaces (Figure 3F). If we interpret the data correctly, the close association of 
these particular vessels with pneumocytes, deep within the metastasis, indicates that these 
are co-opted alveolar capillaries rather than newly formed vessels. However, we cannot 
completely rule-out the possibility that angiogenesis is occurring as well in this growth 
pattern, especially in the centre of the metastasis.  We named this growth pattern the 
interstitial HGP due to the propensity for cancer cells to grow within the alveolar interstitium, 
and to be consistent with a previous report of a similar growth pattern [14].  
 
Co-option of large blood vessels in the perivascular cuffing growth pattern  
 Thus far, we have described two mechanisms via which cancer cells co-opt alveolar 
capillaries. However, the lungs also contain larger vessels (i.e. arteries and veins) which are 
distinct from alveolar capillaries because of their larger calibre and because they are 
surrounded by a layer of smooth muscle cells (the tunica media) (Supplementary Figure 
8A,B). In the perivascular cuffing HGP of human lung metastases, the cancer cells grow 
exclusively like a cuff around these larger vessels (Supplementary Figure 8C-F). The cuff 
can be several layers of cancer cells thick, but is devoid of additional blood vessels. Our 
interpretation of these data is that the cancer cells utilise the central co-opted vessel as their 
principle vascular supply in this growth pattern.  
 
Frequency of the different growth patterns in human lung metastases  
 To evaluate the frequency of the alveolar, interstitial, perivascular cuffing and pushing 
HGPs in human lung metastases, all 164 cases were scored for their HGP (Figure 4A-C). Of 
note, some lesions presented with more than one growth pattern. Therefore, the percentage 
of the tumour-lung interface adopting each growth pattern was scored in intervals of 5%.  
 To formally analyse the prevalence of vessel co-option across the different tumour 
types, growth patterns that utilise vessel co-option (alveolar, interstitial and perivascular 
cuffing) were pooled together and their incidence was compared to the incidence of the 
 angiogenic pushing growth pattern. Vessel co-opting growth patterns were present to some 
extent (≥5% of tumour-lung interface) in 91.3% of breast, 98.2% of colorectal and 62.3% of 
renal cancer metastases. Moreover, vessel co-opting growth patterns were dominant (≥75% 
of tumour-lung interface) in 71.7% of breast, 78.9% of colorectal and 37.7% of renal cancer 
metastases. Vessel co-opting growth patterns were more common both in breast cancer 
compared to renal cancer (P = 0.0008, Fisher’s exact test) and in colorectal cancer 
compared to renal cancer (P < 0.0001, Fisher’s exact test). 
 Breast cancer metastases were also characterised for intrinsic molecular subtype: 
luminal A, luminal B (HER2-negative), luminal B (HER2-positive), HER2 positive (non-
luminal) and triple negative. Vessel co-opting growth patterns were present across all 
subtypes (Supplementary Figure S9). However, vessel co-option was less prevalent in triple 
negative tumours compared with other subtypes (P = 0.022, Fisher’s exact test). 
 
Limited efficacy of sunitinib in lung metastasis models compared to subcutaneously 
implanted tumours  
 Conventional anti-angiogenic therapies were designed to inhibit new blood vessel 
growth, but were not designed to target vessel co-option. To address whether vessel co-
option could mediate resistance to anti-angiogenic therapy in lung metastases, we utilised 
three preclinical syngeneic tumour models corresponding to the three types of human cancer 
studied above. The 4T1 cell line was used to model breast cancer, whilst the C26 and 
RENCA cell lines were used to model colorectal and renal cancer, respectively. To examine 
the response to anti-angiogenic therapy, we utilised the potent anti-angiogenic tyrosine 
kinase inhibitor sunitinib.  
 Since the growth of subcutaneously-implanted tumours is known to be angiogenesis-
dependent, we first assessed sunitinib activity against subcutaneously implanted 4T1, C26 
and RENCA tumours. Treatment with 40 mg/kg/day sunitinib for 10 days significantly 
suppressed both tumour vessel density and tumour burden in all three models (Figure 5A-C), 
 confirming the ability of sunitinib to suppress tumour angiogenesis and tumour growth in 
these three angiogenesis-dependent tumour models.  
 We then addressed the response to sunitinib in lung metastases formed by the same 
cell lines. Lung metastases were established by intravenous tail vein injection of 4T1, C26 or 
RENCA cells. In contrast to its potent activity against subcutaneously-implanted tumours, the 
same sunitinib treatment regimen (40 mg/kg/day sunitinib for 10 days) did not significantly 
suppress tumour vessel density in any of the lung metastasis models (Figure 5D-F).  In 
addition, sunitinib treatment did not reduce tumour burden in either 4T1 or C26 lung 
metastases (Figure 5D,E).  Sunitinib treatment did significantly suppress tumour burden by 
~34% in RENCA lung metastases (Figure 5F). However, this activity is modest when 
compared to subcutaneously-implanted RENCA tumours in which the same treatment 
regimen suppressed tumour burden by ~80% (Fig 5C).  
 
Evidence that vessel co-option mediates resistance to sunitinib in 4T1 and C26 lung 
metastases 
 To determine why the lung metastases responded so poorly to this anti-angiogenic 
drug, we examined the histopathological growth pattern of all three lung metastasis models 
(Figure 6). 4T1 and C26 lung metastases had an irregular margin and were highly infiltrative 
into the lung parenchyma (Figure 6A,E). Closer examination revealed that the cancer cells 
colonised the lung by growing in the alveolar air spaces and / or by growing in the alveolar 
walls (Supplementary Fig S10). Staining for the pneumocyte marker CK7 revealed that the 
alveolar walls of the lung were clearly incorporated into the metastases (Figure 6B,F). 
Moreover, co-staining for CK7 and the blood vessel marker CD34 highlighted the presence 
of blood vessels in these tumours that were still associated with alveolar epithelial cells, 
showing that these tumours incorporate alveolar capillaries (Figure 6C,G). Therefore, the 
4T1 and C26 models have a growth pattern that mimics the alveolar / interstitial HGP of 
human lung metastases and these tumours co-opt pre-existing alveolar capillaries. 
Quantification of the growth pattern in 4T1 and C26 lung metastases revealed that this 
 alveolar / interstitial HGP was the dominant growth pattern in both the vehicle- and sunitinib-
treated mice (Figure 6D,H).  
 Our interpretation of these data is that the 4T1 and C26 models of lung metastasis 
co-opt pre-existing alveolar capillaries and that these co-opted vessels are not sensitive to 
sunitinib treatment. These data provide a potential mechanistic explanation for the inability of 
sunitinib to control tumour burden in these lung metastasis models.  
 
 
Evidence that a switch from angiogenesis to vessel co-option mediates resistance to 
sunitinib in RENCA lung metastases 
 The situation was more complex for RENCA lung metastases, which presented with a 
mixture of pushing HGP metastases (Figure 6I-K) and alveolar / interstitial HGP metastases 
(Figure 6L-N). In vehicle-treated mice, the pushing HGP was the prevalent growth pattern of 
RENCA lung metastases (Figure 6O). These pushing HGP metastases had a strikingly 
spherical or ‘cannon ball’ shape (Figure 6I) and, instead of invading into the lung 
parenchyma, these tumours pushed the alveolar walls away (Figure 6J). The blood vessels 
in pushing HGP metastases were not associated with CK7-positive pneumocytes, suggesting 
that these tumours vascularise through angiogenesis instead of vessel co-option (Figure 6K).  
 However, in sunitinib-treated mice, the alveolar / interstitial HGP was the prevalent 
growth pattern of RENCA lung metastases (Figure 6O). RENCA lung metastases with an 
alveolar / interstitial HGP had an irregular margin and infiltrated the lung parenchyma (Figure 
6L). Staining for CK7 revealed incorporation of alveolar walls into the metastases (Figure 
6M) and co-staining for CD34 and CK7 highlighted that these tumours incorporate pre-
existing alveolar capillaries (Figure 6N).  
 In the analysis of vessel density in RENCA lung metastases described above (Figure 
5F), vessel density was quantified across the entire tissue section without regards to the 
growth pattern. We therefore re-examined vessel density in RENCA lung metastases by 
quantifying, separately, the vessel density in pushing HGP lesions and the vessel density in 
alveolar / interstitial HGP lesions. Importantly, whilst vessel density was significantly lower in 
 pushing HGP RENCA lesions from sunitinib-treated mice compared to the vehicle group 
(Supplementary Figure S11A-C), no significant difference in vessel density was observed in 
alveolar / interstitial HGP RENCA lesions from sunitinib-treated mice compared to the vehicle 
group (Supplementary Figure S11D-F). 
 Our interpretation of these data is that: (a) the vessels of angiogenic pushing growth 
pattern RENCA lung metastases are sensitive to sunitinib and (b) sunitinib also induces a 
rapid shift in growth pattern to the alveolar / interstitial HGP, which permits the co-option of 
alveolar capillaries that are resistant to sunitinib. This provides a potential mechanistic 
explanation as to why sunitinib only has a modest effect on tumour burden in the RENCA 
lung metastasis model. 
 
  
 Discussion 
 Here we examined the mechanisms of tumour vascularisation in human lung 
metastases. We report three distinct growth patterns of human lung metastases where, if our 
interpretation of the histology is correct, the co-option of pre-existing vessels occurs via three 
distinct mechanisms. In the alveolar HGP, cancer cells invade the alveolar air spaces, which 
facilitates the co-option of the alveolar capillaries that lie within the incorporated alveolar 
walls. In the interstitial HGP, cancer cells infiltrate the alveolar walls, which again allows the 
co-option of alveolar capillaries, albeit via a mechanism that is distinct from the alveolar 
HGP. In the perivascular cuffing HGP, cancer cells grow as a cuff around large pre-existing 
vessels of the lung, resulting in the co-option of these larger vessels. We also report a 
pushing HGP where the lung metastases present with a chaotically organised vasculature 
that is typical of tumour angiogenesis. Our interpretation of these data is that lung 
metastases can vascularise by co-opting pre-existing vessels of the lung (via three distinct 
mechanisms) or they can utilise angiogenesis. Moreover, rather than being a rare event, we 
found that vessel co-option occurs frequently in human lung metastases. 
 We do acknowledge, however, that both angiogenesis and vessel co-option can 
occur within the same lesion. In support of this, here we observed that lung metastases can 
present with a mixture of growth patterns e.g. lesions where the pushing HGP and the 
alveolar HGP were both present, but in different areas of the same lesion. Moreover, in both 
the alveolar HGP and the interstitial HGP, it is possible that new vessels can sprout from co-
opted vessels once the co-opted vessels are in the centre of the metastasis. In support of 
this, studies on NSCLC have shown that many of these tumours can invade the alveolar air 
spaces at the tumour periphery (permitting vessel co-option), but that a switch to 
angiogenesis then occurs in the centre of the tumour [8,9]. Presumably this occurs because 
vessels co-opted at the periphery are induced to undergo angiogenesis when they find 
themselves within the centre of the tumour. We therefore propose that there is both spatial 
heterogeneity, and temporal heterogeneity, in the vascularisation mechanisms used by 
human tumours, with lesions able to utilise either angiogenesis or vessel co-option or both.  
  It is not currently clear why cancer cells utilise vessel co-option instead of, or as well 
as, activating angiogenesis when they metastasise to the lung. Previous work has suggested 
that, although micrometastases can rely on vessel co-option, tumours must switch to a 
reliance on angiogenesis as they become larger [30]. However, in the current study, we 
observed vessel co-option even in human lung metastases that were large (≥ 1 cm  in 
diameter). If we interpret these data correctly, we must conclude that vessel co-option can be 
a mechanism of tumour vascularisation in both micrometastases and macrometastases. In 
addition, our data suggest that tumours of diverse primary origin (i.e. breast, bowel and 
kidney) can all utilise vessel co-option when they metastasise to lung. Given this evidence, it 
seems probable that the environment of the lung plays an active role in inducing cancer cells 
to utilise vessel co-option instead of angiogenesis. 
  We also provide evidence that vessel co-option mediates intrinsic resistance to anti-
angiogenic therapy in preclinical lung metastasis models. Whilst the anti-angiogenic drug 
sunitinib suppressed the growth of angiogenesis-dependent subcutaneously-implanted 4T1 
and C26 tumours, the lung metastases of 4T1 and C26 utilised vessel co-option and 
displayed intrinsic resistance to this same anti-angiogenic drug. Further evidence that vessel 
co-option mediates intrinsic resistance to anti-angiogenic therapy comes from a spontaneous 
breast cancer metastasis model using the highly metastatic MDA-MB-231LM2-4 breast cancer 
cell line. We reported previously that whilst the growth of MDA-MB-231LM2-4 tumours is 
significantly suppressed by sunitinib when these cells are implanted orthotopically in the 
mammary fat pad, administration of sunitinib does not prolong the survival of mice bearing 
spontaneous MDA-MB-231LM2-4 metastases [31]. Importantly, we found that whilst mammary 
fat pad-implanted MDA-MB-231LM2-4 tumours are angiogenic, spontaneous MDA-MB-231LM2-4 
lung metastases utilise vessel co-option (Harold Dvorak and Robert Kerbel, unpublished 
observation). In confirmation, staining for CK7 and CD34 in spontaneous MDA-MB-231LM2-4 
lung metastases demonstrates that these tumours have an alveolar HGP and that they do 
co-opt alveolar capillaries (Supplementary Figure S12). If we interpret these data correctly, 
vessel co-option is therefore associated with intrinsic resistance to sunitinib, not just in 
 intravenous models of lung metastasis (i.e. 4T1 and C26), but also in a model of 
spontaneous breast cancer lung metastasis using a human breast cancer cell line (i.e. MDA-
MB-231LM2-4).  
 Vessel co-option might also mediate acquired resistance to anti-angiogenic therapy. 
Although RENCA lung metastases presented mainly as angiogenic pushing HGP lesions in 
vehicle-treated mice, sunitinib induced a switch to an alveolar / interstitial HGP that 
vascularises by vessel co-option. Importantly, whilst the vessels of pushing HGP metastases 
were sensitive to sunitinib, the vessels of alveolar / interstitial HGP lung metastases were 
not. Our interpretation of these data is that a treatment-induced switch from angiogenesis to 
vessel co-option could drive acquired resistance to anti-angiogenic therapy. In further 
support of this, Kuczynski et al recently showed that a switch from angiogenesis to vessel co-
option drives acquired resistance to the anti-angiogenic drug sorafenib in hepatocellular 
carcinoma [20]. Moreover, a switch from angiogenesis to vessel co-option is reported to 
occur in some brain malignancies treated with anti-angiogenic therapy [17-19,23,24]. 
 Four phase 3 trials have tested sunitinib in metastatic breast cancer, with no benefit 
in either progression free survival (PFS) or overall survival (OS) demonstrated for sunitinib 
[32-35]. If the quantification of vessel co-option in human breast cancer lung metastases 
presented here is representative of breast cancer patients as a whole, many patients 
entering these trials will have presented with breast cancer metastases to the lung that 
vascularise through vessel co-option. In addition, vessel co-option occurs in breast cancer 
metastases to the skin [36], lymph nodes [21,37], liver [22,38] and brain [39-41]. Therefore, 
vessel co-option may help to explain, at least in part, why anti-angiogenic therapy has been a 
disappointing therapeutic approach in metastatic breast cancer.  
 In contrast to breast cancer, sunitinib extends both PFS and OS in metastatic renal 
cancer [42,43]. Here we found that vessel co-option occurs less frequently in human renal 
cancer lung metastases when compared to human breast cancer lung metastases. This 
disparity may help to explain why sunitinib is a clinically more effective treatment for 
metastatic renal cancer, compared to metastatic breast cancer. Nonetheless, both intrinsic 
 and acquired resistance to anti-angiogenic drugs occurs in renal cancer patients [44,45]. 
Moreover, despite showing activity in the advanced disease setting, sunitinib did not prolong 
disease-free survival (DFS) in renal cancer patients who received this drug as adjuvant 
therapy [46]. We propose that vessel co-option may help to explain resistance to anti-
angiogenic therapy in both the metastatic setting and the adjuvant setting in renal cancer. 
  In conclusion, if we interpret our data correctly, vessel co-option is a common event 
in human lung metastases that occurs via three distinct mechanisms. Moreover, our data 
suggest that vessel co-option may drive resistance to anti-angiogenic therapy in preclinical 
lung metastasis models. One limitation of our study is that, due to a lack of sufficient lung 
metastasis samples from patients treated with anti-angiogenic therapy, we have not been 
able to examine if there is an association between vessel co-option and resistance to anti-
angiogenic therapy in patients. There is, however, clinical data showing that co-option of the 
pre-existing vasculature is associated with resistance to anti-angiogenic therapy in both 
lymph node metastases [21] and liver metastases [22]. Further research is, therefore, now 
warranted to confirm the role of vessel co-option in resistance to anti-angiogenic therapy in 
patients with lung metastases.  
 If vessel co-option does prove to be a common mechanism of resistance to anti-
angiogenic therapy across multiple metastatic sites, then therapeutic approaches that can 
inhibit both angiogenesis and vessel co-option may be warranted for the treatment of 
metastatic disease. However, further research will now be required to establish how both 
modalities of tumour vascularisation can be effectively targeted simultaneously in patients. 
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 Figure Legends   
 
Figure 1 Alveolar and pushing growth patterns of human lung metastases 
A,B. Normal human lung parenchyma, stained for cytokeratin 7 (CK7) (A) or CD31 (B).   
C,D. Alveolar HGP of human breast cancer lung metastasis. Staining for CK7 (at the tumour-
lung interface) is shown in C. Staining for CD31 (within the tumour) is shown in D. 
E,F. Pushing HGP of human breast cancer lung metastasis.  Staining for CK7 (at the tumour-
lung interface) is shown in E. Staining for CD31 (within the tumour) is shown in F. 
Cancer cells (asterisks), alveolar macrophages (arrows), alveolar air space (air), tumour-lung 
interface (dashed line), normal lung (lu). Scale bar, 50 µm. 
 
 
  
 Figure 2 Vessel co-option occurs in the alveolar growth pattern of human lung 
metastases  
A-D. Immunofluorescence co-staining for CD31 (red) and cytokeratin 7 (CK7, green) in a 
case of human breast cancer lung metastasis which presented with an alveolar HGP.  
A. In areas of tumour-free normal lung parenchyma, the alveolar walls are composed of 
CD31-positive alveolar capillaries (red) that are sheathed by CK7-positive pneumocytes 
(green). 
B. At the tumour-lung interface, cancer cells (asterisk) invade into an alveolar air space. 
Arrowheads indicate two CD31-positive alveolar macrophages in the alveolar air space that 
also reacted with the CD31 antibody.  
C. Behind the tumour-lung interface, cancer cells (asterisks) completely fill the alveolar air 
spaces, preserving the alveolar walls and the associated alveolar capillaries.  
D. Towards the centre of the metastatic lesion, co-opted alveolar capillaries can be found 
that are only partially coated by pneumocytes. Arrows indicate pneumocytes that are still 
associated with co-opted alveolar capillaries. Arrowheads indicate autofluorescent 
erythrocytes in the lumen of co-opted alveolar capillaries. 
E-F. Immunofluorescence co-staining for CD31 (red) and CK7 (green) in a sample of human 
renal cancer lung metastasis with a pushing HGP. At the tumour-lung interface, cancer cells 
push the alveolar walls away (E). No incorporation of alveolar walls was observed either at 
the tumour-lung interface (E), or deeper into the metastasis (F).  
Alveolar air space (air), normal lung (lung). Scale bar, 25 µm. 
 
  
 Figure 3 Vessel co-option occurs in the interstitial growth pattern of human lung 
metastases 
Immunohistochemical analysis of a renal cancer lung metastasis with an interstitial HGP, 
illustrating growth of cancer cells within the alveolar walls. Staining for carbonic anhydrase 9 
(CAIX, brown) was used to detect cancer cells, in combination with either cytokeratin 7 (CK7) 
staining (green) to detect pneumocytes (A,C,E) or CD31 staining (green) to detect blood 
vessels (B,D,F). 
A. Tumour-lung interface: alveolar walls filled with cancer cells are present at the top of the 
image (asterisks), whilst tumour-free alveolar walls of the normal lung are present below 
(diamond symbols). 
B. High power view of an alveolar wall is shown (delineated with a dashed line). Asterisks 
indicate cancer cells that are infiltrating around pre-existing alveolar capillaries.  
C,D. Area just behind the tumour-lung interface is shown: the alveolar walls are now 
completely filled with cancer cells. The intervening alveolar air spaces (air) remain intact 
E,F. The centre of the metastasis. In E, asterisks indicate cancer cells that are filling the 
expanded alveolar walls, whilst the intervening alveolar air spaces (air) remain intact. The 
arrow indicates an alveolar air space that has become partially filled with cancer cells. In F, 
arrowheads indicate blood vessels which are closely associated with the abluminal side of an 
alveolar air space.  
Alveolar air space (air). Scale bar, 100 µm (A,C,D,E,F) and 50 µm (B). 
 
  
 Figure 4 Frequency of the different HGPs in lung metastases of human breast, 
colorectal and renal cancer 
A-C. Lung metastases of human breast cancer (A), human colorectal cancer (B) and human 
renal cancer (C) were scored for their growth pattern. Each bar represents an individual case 
of metastasis showing the % of tumour-lung interface scored as alveolar, interstitial, 
perivascular cuffing or pushing HGP. n = 46 breast cancer lung metastases (A), 57 colorectal 
cancer lung metastases (B), and 61 renal cancer lung metastases (C). 
 
 
 
 
 
 
  
 Figure 5 Limited efficacy of sunitinib in lung metastasis models compared to 
subcutaneously implanted tumours 
A-C. The efficacy of sunitinib was tested in mice injected subcutaneously with 4T1 (A), C26 
(B) or RENCA (C) cells. The graphs show tumour vessel density +/- SEM (left) or tumour 
burden +/- SEM (right) in subcutaneous 4T1 (A), C26 (B) or RENCA (C) tumours after 10 
days treatment with either 40 mg/kg/day sunitinib (sun) or vehicle (veh) alone. n = 10 mice 
per experimental group for tumour burden graphs. n = 6 mice per experimental group for 
tumour vessel density graphs.  
D-F. Mice were injected via the tail vein with 4T1 (D), C26 (E) or RENCA (F) cells. The 
graphs show tumour vessel density +/- SEM (left) or tumour burden +/- SEM (right) in the 
lungs after 10 days treatment with either 40 mg/kg/day sunitinib (sun) or vehicle (veh) alone. 
n = 9 or 10 mice per experimental group for tumour burden graphs. n = 5 mice per 
experimental group for tumour vessel density graphs.  
no significant difference (ns). 
 
  
 Figure 6 Evidence for vessel co-option in lung metastasis models  
Histopathological characterisation was performed on lung metastases formed by 4T1 cells 
(A-D), C26 cells (E-H) and RENCA cells (I-O) after tail vein injection. Low power views of 
lung metastasis morphology by H&E staining (A,E,I,L). Higher power views of cytokeratin 7 
stained lung metastases (B,F,J,M) or lung metastases co-stained for CD34 (red) and 
cytokeratin 7 (green) (C,G,K,N). Graphs show % alveolar-interstitial HGP and % pushing 
HGP scored in 4T1 (D), C26 (H) and RENCA (O) lung metastases from vehicle (veh) or 
sunitinib (sun) treated mice (n = 9 or 10 mice per experimental group).  
Cancer cells (asterisk), alveolar air spaces (air), no significant difference (ns).  
Scale bar, 125 µm (A,E,I,L), 20 µm (B,F,J,M) and 20 µm (C,G,K,N).  
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Supplementary materials and methods 
 
Details of primary antibodies  
 The primary antibodies used were: 1:1000 anti-carbonic anhydrase IX (CAIX) 
(ab15086, Abcam, Cambridge, UK), 1:30 anti-CD31 (M0823, Dako, Ely, UK), 1:100 anti-
CD34 (ab8188, Abcam), 1:50 anti-cytokeratin 7 (CK7) (sc23876, Santa Cruz, Dallas, TX), 
1:80 anti-oestrogen receptor alpha (ERα) (M3643, Dako), 1:300 anti-Ki67 (M7240, Dako), 
1:200 anti-progesterone receptor (PgR) (M 3569, Dako) and 1:50 anti-thyroid transcription 
factor 1 (TTF1) (M3575, Dako).  
 
Staining of tissue sections 
 For staining of human and mouse tissue, 4 µm sections from FFPE blocks were de-
paraffinised and rehydrated by standard protocols. Antigen retrieval was performed either at 
pH 6 in a pressure cooker or at pH 9 in a microwave. Sections were incubated for 1 h at 
room temperature or overnight at 4 °C with primary antibodies diluted in REAL diluent 
(DAKO). For immunofluorescence, primary antibodies were detected with Alexa-488 or 
Alexa-555 fluorescently-conjugated secondary antibodies (Invitrogen) diluted in REAL diluent 
supplemented with DAPI for 30 mins at room temperature, followed by mounting under glass 
coverslips in MOWIOL mountant supplemented with anti-fade (0.1% w/v 1,4-
diazabicyclo[2,2,2]octane) (Sigma). For DAB and tetramethylbenzidine (TMB) staining, 
primary antibodies were detected with Envision Flex system (K8002, Dako), followed by a 
light counterstain with haematoxylin before mounting under glass coverslips in DPEX 
mountant. HER2 was detected using the HercepTest kit (SK001, Dako). Images were 
captured using a confocal laser-scanning microscope (Leica) or a light microscope 
(Olympus), as appropriate.  
 
  
Scoring of histopathological growth patterns in human lung metastasis specimens 
 All lung metastasis cases underwent four different stainings which were used to score 
the histopathological growth pattern (HGP): (a) H&E stain, (b) immunohistochemistry for a 
pneumocyte marker (usually CK7, but TTF1 was also used for breast cancer), (c) 
immunohistochemistry for a blood vessel marker (CD31) and (d) immunofluorescence co-
staining for a pneumocyte marker (CK7 or TTF1) and CD31. All specimens were digitally 
scanned using a semi-automated scanning microscope (Hamamatsu Nanozoomer) and 
HGPs were scored by reviewing the images using NDPI viewer software (Hamamatsu). 
Metastases were scored as having an alveolar, interstitial, perivascular cuffing or pushing 
HGP according to the following criteria. Alveolar HGP: the metastasis presented with an 
intra-alveolar growth pattern, where cancer cells invaded into the alveolar air spaces at the 
tumour-lung interface and there was incorporation of intact alveolar walls (and their 
associated capillaries) into the metastasis.  Interstitial HGP: cancer cells invaded into the 
alveolar walls at the tumour-lung interface, facilitating the incorporation of the associated 
capillaries into the metastasis. Incorporation of intact alveolar air spaces into the metastasis 
was always clearly visible in the interstitial HGP. Perivascular cuffing HGP: cancer cells grew 
as a cuff around large pre-existing vessels of the lung. Pushing HGP: the cancer cells 
pushed the lung parenchyma away at the periphery of the metastasis (leading to 
compression and flattening of the adjacent alveolar walls) and the tumour vasculature did not 
resemble the vasculature of the normal lung parenchyma. To account for lesions presenting 
with a mixture of different HGPs, the percentage of the tumour-lung interface adopting the 
alveolar, interstitial, perivascular cuffing or pushing HGP was scored in intervals of 5% for 
each metastasis. 
 In the alveolar HGP, it was sometimes observed that cancers cells also invaded into 
the alveolar walls after those walls were incorporated into the metastasis. Such cases were 
scored as having an alveolar HGP when the intra-alveolar growth pattern was predominant 
at the tumour-lung interface. In the interstitial HGP, it was sometimes observed that cancer 
cells could invade into the air spaces after those air spaces were incorporated into the 
metastasis. Such cases were scored as having an interstitial HGP when the interstitial 
growth pattern was predominant at the tumour-lung interface. 
 
Scoring intrinsic subtypes of breast cancer in lung metastasis samples 
Cases of breast cancer lung metastasis were characterized for intrinsic molecular 
subtype: luminal A, luminal B-HER2 negative, luminal B-HER2 positive, HER2 positive (non-
luminal) and triple negative using surrogate immunohistochemical markers as recommended 
in recently published guidelines [23]. In brief, FFPE tissue sections were stained for ER, 
PgR, HER2 or Ki67 and were then scored. For both ER and PgR, positive staining in ≥1% of 
tumour cell nuclei was required in order for the case to be considered receptor positive [24]. 
For HER2, the following system was utilized:  0 or 1+ (HER2 negative), 2+ (HER2 
borderline), or 3+ (HER2 positive) [25]. Cases scored as HER2 borderline underwent 
additional testing with the HER2 CISH pharmDx kit (SK109, Dako) to test for HER2 
amplification according to the manufacturer’s instructions. The presence of HER2 
amplification was considered to indicate that the case was HER2 positive. Cases were 
deemed Ki67 ‘low’ if <14% of nuclei were Ki67 positive, otherwise they were considered to 
be Ki67 ‘high.’  
The results of the ER, PgR, HER2 and Ki67 analyses were then used to assign each 
case to an intrinsic molecular subtype according to the criteria shown below and in 
accordance with published guidelines [23]: 
 
Intrinsic subtype Criteria 
Luminal A ER and PgR positive 
HER2 negative 
Ki67 ‘low’  
Luminal B HER2 negative ER positive 
HER2 negative 
Ki67 ‘high’ 
Luminal B HER2 positive ER positive 
HER2 positive 
Any Ki67 
Any PgR 
HER2 positive (non-luminal) HER2 positive 
ER and PgR both negative 
Triple negative Negative for ER, PgR and HER2 
 
Cell culture  
 
 The murine cancer cell lines (4T1, C26 and RENCA) were cultured on plastic and 
maintained at 37°C / 5% CO2 in RPMI supplemented with 10% FCS. All cell lines were 
regularly checked for mycoplasma and shown to be contamination free. 
 
Preparation of sunitinib for oral dosing 
 Vehicle for sunitinib consisted of 0.5 % w/v carboxymethylcellulose sodium, 1.8 % w/v 
NaCl, 0.4 % w/v Tween-80, 0.9 % w/v benzyl alcohol dissolved in reverse osmosis deionised 
water adjusted to pH 6. For oral dosing, sunitinib malate powder was added to vehicle and 
vortexed to create a suspension. Fresh stocks of sunitinib suspension were prepared weekly 
and stored at 4 °C in the dark. Oral dosing of mice was performed by administration of 0.2 ml 
of vehicle or sunitinib suspension by oral gavage. 
 
Mouse models 
 The Institute of Cancer Research Animal Ethics Committee granted approval for 
animal work and procedures were performed in accordance with the United Kingdom Home 
Office regulations. Female Balb/c mice at 8 - 12 weeks of age (Charles River) were used for 
all in vivo studies. To establish subcutaneous tumours, mice were injected with 2x105 4T1 
cells, 2x105 C26 cells or 1x106 RENCA cells. Once tumours reached a volume of 50-100 
mm2, mice were randomised to treatment with 40 mg/kg/day sunitinib or vehicle alone. After 
10 days of treatment the mice were culled and the tumours were harvested. After 
measurement with callipers the tumours were fixed in formalin overnight. Tumour volumes 
were calculated using the formula: (length x width2)/2. To establish lung metastases, mice 
were injected with 2x105 4T1, C26 or RENCA cells via the tail vein. Mice injected with 4T1 or 
C26 cells were randomised to treatment with sunitinib or vehicle alone on the day after 
injection. Due to the slower growth rate of RENCA lung metastases, mice injected with 
RENCA cells were randomised to treatment with sunitinib or vehicle alone at 10 days after 
injection. In all three models, mice were culled after 10 days of treatment. The lungs were 
then fixed by infusion of formalin into the lungs via the trachea, followed by immersion in 
formalin to fix overnight.  
 For quantification of tumour burden, digitally scanned H&E-stained sections of mouse 
lung were viewed using NDPI viewer software. The marquee tool in the software package 
was used freehand to measure both areas of tumour (a) and the total area of the lung (b). To 
calculate tumour burden, the percentage area of lung section that was occupied by tumour 
was then calculated according to this formula: (a / b) x 100. For quantification of vessel 
density in both subcutaneous tumours and lung metastases, sections were stained for CD34 
and the number of CD34-positive tumour vessels was counted. Vessel density was 
expressed in terms of the number of vessels per mm2 of tumour tissue.  
 
 
Supplementary figure legends 
 
  
Figure S1. Consort diagram for breast cancer lung metastasis cases 
Consort diagram to demonstrate the selection of breast cancer lung metastasis 
cases for this study.  Where samples were excluded, the reasons for exclusion are 
indicated. 
 
 
Figure S2. Consort diagram for colorectal cancer lung metastasis cases 
Consort diagram to demonstrate the selection of colorectal cancer lung metastasis 
cases for this study.  Where samples were excluded, the reasons for exclusion are 
indicated. 
 
 
Figure S3. Consort diagram for renal cancer lung metastasis cases 
Consort diagram to demonstrate the selection of renal cancer lung metastasis cases 
for this study.  Where samples were excluded, the reasons for exclusion are 
indicated. 
 
 
Figure S4. Alveolar HGP and pushing HGP of colorectal cancer lung 
metastases  
A,B. Alveolar HGP of colorectal cancer lung metastasis. Panel A shows tumour-lung 
interface stained for cytokeratin 7 (CK7). Note the presence of cancer cells 
(asterisks) within the alveolar air spaces. Panel B shows an intra-tumoural region 
stained for CD31. Note that the vascular architecture of the tumour mimics the 
vascular architecture of normal lung parenchyma (see Figure 1B for CD31 staining of 
normal lung for comparison).  
C,D. Pushing HGP of colorectal cancer lung metastasis. Panel C shows tumour-lung 
interface stained for cytokeratin 7 (CK7). Note that the cancer cells (asterisks) push 
the alveolar walls away. Panel D shows an intra-tumoural region stained for CD31. 
Note that the vasculature is chaotic which is typical for the process of tumour 
angiogenesis.  
Cancer cells (asterisk), normal lung (lu). Scale bars, 50 µm. 
 
 
Figure S5. Alveolar HGP and pushing HGP of renal cancer lung metastases 
A,B. Alveolar HGP of renal cancer lung metastasis. Panel A shows tumour-lung 
interface stained for cytokeratin 7 (CK7). Note the presence of cancer cells 
(asterisks) within the alveolar air spaces. Panel B shows an intra-tumoural region 
stained for CD31. Note that the vascular architecture of the tumour mimics the 
vascular architecture of normal lung parenchyma (see Figure 1B for CD31 staining of 
normal lung for comparison). 
C,D. Pushing HGP of renal cancer lung metastasis. Panel C shows tumour-lung 
interface stained for cytokeratin 7 (CK7). Note that the cancer cells (asterisks) push 
the alveolar walls away. Panel D shows an intra-tumoural region stained for CD31. 
Note that the vasculature is chaotic which is typical for the process of tumour 
angiogenesis.  
Cancer cells (asterisk), normal lung (lu). Scale bars, 50 µm. 
 
 
 
Figure S6. Examples of co-opted alveolar capillaries in human lung metastases 
A-C. Immunofluorescence co-staining for CD31 (red) and cytokeratin 7 (CK7, green) 
in human lung metastases presenting with an alveolar  HGP.  Examples of co-opted 
alveolar capillaries are shown from lung metastases of human breast cancer (A), 
human colorectal cancer (B) and human renal cancer (C). 
D,E. Serial sections from a case of human breast cancer lung metastasis with an 
alveolar HGP were stained for H&E (D) or cytokeratin 7 (CK7) (E). Arrows point to 
erythrocytes within a co-opted alveolar capillary, indicating that the co-opted vessel is 
perfused and functional.  
Cancer cells (asterisks), co-opted alveolar capillaries (arrowheads), erythrocytes 
(arrows). Scale bars, 25 µm. 
 
 
Figure S7. Pattern of pneumocyte staining in the alveolar HGP 
Lower power view of a human breast cancer lung metastasis, which presented with 
an alveolar HGP. The case has been stained for the pneumocyte marker cytokeratin 
7 (CK7). Three zones are indicated: zone 1 (normal lung), zone 2 (periphery of the 
metastasis where the alveolar epithelium is mostly preserved within the metastasis) 
and zone 3 (centre of the metastasis where the alveolar epithelium begins to 
fragment). Dotted line indicates the tumour-lung interface.  
Scale bar, 500 µm. 
 
 
Figure S8. Vessel co-option in the perivascular cuffing growth pattern of 
human lung metastases 
A,B. Images of normal human lung parenchyma stained for CD31. Arrows indicate 
large blood vessels. Arrowheads indicate the surrounding smooth muscle layer 
(tunica media). 
C,D. Images of human breast cancer lung metastasis with a perivascular-cuffing 
HGP stained for CD31. The central co-opted vessel is indicated (arrow). The cancer 
cells that form a cuff around the vessel are also indicated (asterisks) 
E,F. Images of a human breast cancer lung metastasis with a perivascular-cuffing 
HGP which was stained for oestrogen receptor alpha (ERα) to detect the cancer 
cells. The ERα-positive cancer cells (asterisks) grow as a cuff around the large 
vessels. Arrows indicate the large central vessels that are co-opted.  
Scale bar, 50 µm. 
 
 
Figure S9. Cases of breast cancer lung metastases grouped by intrinsic 
molecular subtype 
Graph shows the HGPs for 46 cases of breast cancer lung metastases (the same as 
scored in Figure 4A) grouped here by intrinsic molecular subtype. 
Lum A = luminal A; Lum B (HER2-) = luminal B (HER2 negative); Lum B (HER2+) = 
luminal B (HER2 positive); HER2+ (non-lum) = HER2 positive (non-luminal) and TN 
= triple negative. For one of the cases we were unable to determine the subtype due 
to lack of sufficient tissue samples (ND, not determined).  
 
 
 
  
Figure S10. High power views of alveolar growth pattern and interstitial growth 
pattern in preclinical lung metastasis models 
A. Alveolar growth pattern. In lung metastases formed by 4T1 cells, groups of 4T1 
cells growing in alveolar air spaces are indicated with an arrowhead.  
B. Interstitial growth pattern. In lung metastases formed by C26 cells, groups of C26 
cells that are  growing within the alveolar walls are indicated with asterisks.  
Scale bar, 100 µm. 
 
 
Figure S11. Contrasting effect of sunitinib in RENCA lung metastases with 
different HGPs 
A-F. Graphs show tumour vessel density +/- SEM in lung metastases from mice 
injected via the tail vein with RENCA cells and then treated for 10 days with either 40 
mg/kg/day sunitinib (sun) or vehicle (veh) alone (A,D). Vessel density was quantified 
in pushing lung metastases (A) or alveolar-interstitial lung metastases (D) separately. 
n = 20 lung metastases (from 5 mice) per data point. Representative images of CD34 
staining in pushing lung metastases (B,C) and alveolar-interstitial lung metastases 
(E,F) from vehicle (B,E) or sunitinib (C,F) treated mice are shown.  
No significant difference (ns). 
 
 
Figure S12. Vessel co-option in spontaneous MDA-MB-231LM2-4 lung 
metastases  
A,B. Staining for CD34, to demonstrate blood vessels (red), and cytokeratin 7 (CK7), 
to demonstrate pneumocytes (green), in normal mouse lung (A) or spontaneous lung 
metastases of MDA-MB-231LM2-4 cells (B). Note that the alveolar structure of the 
normal lung (A) is preserved within the lung metastases (B) indicating that the lung 
metastases in this model grow with an alveolar HGP and co-opt pre-existing alveolar 
capillaries. Asterisks indicate breast cancer cells present in the alveolar air spaces. 
Arrows indicate alveolar macrophages. Scale bar, 20 µM. 
 
 
 
Supplementary Figure S1
Specimens of breast cancer lung metastases 
obtained from:
Antwerp (10 lesions from 10 patients)
Budapest (25 lesions from 25 patients)
Vienna ( 24 lesions from 20 patients)
Total = 59 lesions from 55 patients
Specimens excluded for the following reasons:
Poor tissue quality: 3 lesions
No cancer cells present in specimen: 4 lesions
Cancer cells present in a lymph node only or in the 
pleura only: 4 lesions 
Insufficient tumour-lung interface present for reliable
assessment of HGPs: 2 lesions 
Final cohort included in the analysis:
Antwerp (n= 10 lesions from 10 patients)
Budapest (n= 23 lesions from 23 patients)
Vienna (n = 13 lesions from 13 patients)
Total = 46 lesions from 46 patients
Retrievel of FFPE blocks, preparation of H&E 
stained sections and histopathological review  
to determine suitability for the study
Specimens of colorectal cancer lung metastases 
obtained from:
Antwerp (n= 15 lesions from 11 patients)
Vienna (n = 55 lesions from 53 patients)
Total = 70 lesions from 64 patients
Final cohort included in the analysis:
Antwerp (n= 15 lesions from 11 patients)
Vienna (n = 42 lesions from 42 patients)
Total = 57 lesions from 53 patients
Specimens excluded for the following reasons:
Poor tissue quality: 4 lesions
No cancer cells present in specimen: 6 lesions
Insufficient tumour-lung interface present for reliable
assessment of HGPs: 3 lesions
Supplementary Figure S2
Retrievel of FFPE blocks, preparation of H&E 
stained sections and histopathological review  
to determine suitability for the study
Specimens of renal cancer lung metastases 
obtained from:
Antwerp (6 lesions from  5 patients)
Budapest (47 lesions from 46 patients)
Vienna (11 lesions from 11 patients)
Total =  64 lesions from 62 patients
Specimens excluded for the following reason:
Insufficient tumour-lung interface present for reliable
assessment of HGPs:  3 lesions
Supplementary Figure S3
Retrievel of FFPE blocks, preparation of H&E 
stained sections and histopathological review  
to determine suitability for the study
Final cohort included in the analysis:
Antwerp (n= 6 lesions from 5 patients)
Budapest (n= 44 lesions from 43 patients)
Vienna (n = 11  lesions from 11 patients)
Total =  61 lesions from  59 patients
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Supplementary Table S1 Clinical characteristics of breast cancer 
patients  
 
Clinical characteristics of 46 patients with breast cancer lung metastases that 
were included in the study. 
 
Gender, number of patients (%) 
 Male 
 Female 
 
2 (4.3) 
44 (95.7) 
Age when lung metastasis sample was obtained,  
median (range)  
 
60 (30-82) 
Source of sample, number of patients (%) 
 Surgical resection 
 Autopsy 
 
43 (93.5) 
3 (6.5) 
Size of lung metastasis analysed, number of lesions (%) 
  < 10 mm 
  10  – 19 mm 
              20 – 39 mm 
              ≥ 40 mm 
              N/A 
 
12 (26.1) 
15 (32.6) 
9 (19.6) 
1 (2.1) 
9 (19.6) 
Systemic therapy received by patient prior to resection of 
lung metastasis, number of patients (%)* 
 None  
             Chemotherapy  
 Endocrine therapy 
 Bevacizumab 
             Herceptin  
 Bisphosphonate 
             N/A  
 
 
10 (21.7) 
30 (65.2) 
12 (26.1) 
2 (4.3) 
1 (2.2) 
1 (2.2) 
3 (6.5) 
 
Footnote:  
N/A, accurate information was not available. 
* Some patients received multiple lines of therapy. 
 
  
Supplementary Table S2 Clinical characteristics of colorectal cancer 
patients  
 
Clinical characteristics of 53 patients with colorectal cancer lung metastases that 
were included in the study. 
 
Gender, number of patients (%) 
 Male 
 Female 
 
30 (57) 
23 (43) 
Age when lung metastasis sample was obtained,  
median (range)  
 
63 (33-83) 
Source of sample, number of lesions (%) 
 Surgical resection 
 Autopsy 
 
53 (100) 
0 (0) 
Size of lung metastasis analysed, number of lesions (%) 
  < 10 mm 
  10  – 19 mm 
              20 – 39 mm 
              ≥ 40 mm 
              N/A 
 
13 (22.8) 
26 (45.6) 
10 (17.5) 
2 (3.5) 
6 (10.5) 
Systemic therapy received by patient prior to resection of 
the lung metastasis, number of patients (%) 
 None  
             Chemotherapy  
             Bevacizumab 
             N/A  
 
 
18 (34) 
19 (35.8) 
3 (5.7) 
17 (32.1) 
 
Footnote:  
N/A, accurate information was not available. 
  
Supplementary Table S3 Clinical characteristics of renal cancer 
patients  
 
Clinical characteristics of 59 patients with renal cancer lung metastases that were 
included in the study. 
 
Gender, number of patients (%) 
 Male 
 Female 
 
42 (71.2) 
17 (28.8) 
Age when lung metastasis sample was obtained,  
median (range)  
 
62 (30-77) 
Source of sample, number of lesions (%) 
 Surgical resection 
 Autopsy 
 
58 (98.3) 
1 (1.7) 
Size of lung metastasis analysed, number of lesions (%) 
  < 10 mm 
  10  – 19 mm 
              20 – 39 mm 
              ≥ 40 mm 
 
14 (23) 
19 (31.1) 
18 (29.5) 
10 (16.4) 
Systemic therapy received by patient prior to resection of 
the lung metastasis, number of patients (%)* 
 None  
             Interferon  
 Chemotherapy 
 Sunitinib 
 Pazopanib 
             Sorafenib 
             Interleukin 2 
             N/A  
 
 
16 (27.1) 
13 (22) 
11 (18.6) 
5 (8.5) 
2 (3.4) 
1 (1.7) 
1 (1.7) 
18 (30.5) 
 
Footnote:  
N/A, accurate information was not available. 
* Some patients received multiple lines of therapy. 
 
 
 
 
 
 
